ResMed Inc.

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027

Resmed reported Q1 FY27 revenue of $1.415 billion, up 6% year-over-year (7% core constant currency), with GAAP diluted EPS of $2.92, up 23%, and non-GAAP diluted EPS of $2.91, up 14%. Non-GAAP gross margin expanded 50 bps to 62.5%, and free cash flow was $374 million; proceeds from the closed MatrixCare divestiture helped fund more than $1.0 billion returned to shareholders via buybacks and dividends. FY27 guidance was reaffirmed: 5-7% core constant currency revenue growth, reported revenue of $5.75-$5.85B, and non-GAAP EPS of $12.00-$12.25. The board declared a $0.66 quarterly dividend and Carol Burt will become Lead Director on November 15, 2026.

•3d ago

Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.

Resmed launched the AirTouch F40, a full face fabric CPAP mask using its proprietary ComfiSoft fabric cushion, in the U.S., available beginning October 28, 2026. The mask builds on the existing AirFit F40 platform with an interchangeable cushion and is designed to fit 96% of users. Resmed cites a 6% increase in 90-day compliance for fabric-cushioned masks versus silicone. The launch reinforces Resmed's connected-care ecosystem (myAir, AirView), where app use alongside AirView has been shown to lift therapy compliance from 70% to 87%.

•13d ago

23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs

Resmed announced a collaboration with 23XI Racing and driver Tyler Reddick to raise awareness about obstructive sleep apnea and the importance of treatment. After being diagnosed with OSA in early 2026, Reddick began using Resmed CPAP therapy and subsequently achieved a historic start to the NASCAR Cup Series season, including winning the Daytona 500. The campaign will feature Resmed branding on Reddick's No. 45 Toyota Camry XSE at upcoming races in Bristol, Talladega and Homestead-Miami.

•2mo ago

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

Resmed reported Q4 revenue of $1.46 billion, up 9% year-over-year, driven by strong demand across its sleep and breathing health portfolio. Non-GAAP diluted EPS grew 16% to $2.95, supported by a 90 basis point expansion in non-GAAP gross margin to 62.3%. For the full fiscal year 2026, revenue increased 10% to $5.65 billion with free cash flow of $1.6 billion. The board declared a 10% increase in the quarterly dividend to $0.66 per share and set FY 2027 guidance to return more than $1.85 billion in capital to shareholders. Operational highlights include the acquisition of Noctrix Health, an agreement to sell the MatrixCare business, and the expansion of product launches including the AirSense 11 and AirCurve 11 in new markets.

•2mo ago

Resmed Announces Agreement to Sell MatrixCare Business

Resmed announced a definitive agreement to sell its MatrixCare business to private equity firm Frazier Healthcare Partners to sharpen its focus on sleep and breathing health. The divestiture excludes Resmed's other software businesses, Brightree and MEDIFOX DAN, and is expected to close in Q1 of fiscal year 2027. Management stated the move aligns with its 2030 strategy to reallocate capital toward high-growth, scalable opportunities in connected home-based care.

•3mo ago

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

ResMed (NYSE: RMD) has agreed to acquire Noctrix Health, a medical technology company specializing in neuromodulation therapies, for $340 million. The deal brings Noctrix’s lead product, Nidra, the first FDA-authorized non-invasive therapy for moderate-to-severe Restless Legs Syndrome, into ResMed’s portfolio. ResMed plans to integrate Nidra’s technology into its broader sleep health ecosystem, expanding patient access and enhancing care delivery for neurological and sleep-related conditions.

•4mo ago

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Resmed has completed its acquisition of Noctrix Health, making it a wholly owned subsidiary and expanding its clinical sleep health portfolio into Restless Legs Syndrome (RLS). The deal brings Noctrix’s Nidra® TOMAC Therapy, an FDA De Novo classified non-pharmacologic treatment for moderate-to-severe RLS, into Resmed’s ecosystem of connected devices and digital health solutions. Noctrix’s therapy is already included in American Academy of Sleep Medicine clinical practice guidelines and supported by 10 peer-reviewed publications, offering Resmed a validated entry into a significant unmet need market.

•5mo ago

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

Resmed reported Q3 revenue of $1.4 billion, up 11% year-over-year, with non-GAAP EPS rising 21% to $2.86 driven by 290 basis points of gross margin expansion. Operating cash flow was $554 million, supporting $262 million in capital returns via $175 million of share repurchases and $87 million in dividends. The board declared a quarterly dividend of $0.60 per share, payable June 18, 2026.

•6mo ago